The five finalists in the Top Founder Under 40 category for the inaugural InnovationMap Awards share the challenges they have had to overcome. Photos courtesy

It's not easy being the youngest person in a room, and that's certainly the case for startup founders looking to make an impact on an industry that's been doing things a certain way since before they were born.

The five finalists of the Top Founder Under 40 category for the InnovationMap Awards presented by Techwave were asked to share their challenges overcame as young founders. Here's what they had to say. Click here to register for the livestream.

"It wasn't until I stood my ground by being persistent, and by not being afraid to hand their responsibilities to someone else, that they finally took me seriously."

Photo courtesy of CaseCTRL

— Pamela Singh of CaseCTRL says. "While working as on a Department of Defense Contract, I was leading a development effort with other older white men who were mostly retired military," she explains."They did not appreciate a young ethnic female giving them orders, and would often ignore my email requests or assigned tasks. At first, I felt defeated, but then I had to remember that although they have a lot of knowledge in general, I was the one with the right knowledge for this specific project."

"Changing the minds of experienced executives, who have worked in the energy industry for decades, was an uphill battle that took time and a considerable amount of effort."

With fresh funds, this Houston entrepreneur plans to scale his industrial e-commerce startup

Photo by Colt Melrose for GoExpedi

— Tim Neal of GoExpedi. "Over the years, I have enjoyed great success in my professional career, but that has not come without a few challenges," Neal says. "I am incredibly grateful for my mentors who believed in my vision despite my age."

"I think my go getter attitude has always helped me out and aid me mature faster."

Photo courtesy of LAMIK Beauty

— Kim Roxie of LAMIK Beauty. "Since I started at such young age at 21, after being labeled 'at risk' in high school, I think I have always been seen as 'too young,'" she says. "However, My life motto is 'qualify yourself!'"

"Once I started just being myself and not carrying the weight of the no's it really improved my productivity, my leadership, and my overall success as a person and as a leader in my business."

Emily Cisek, CEO and co-founder of The Postage

Photo courtesy of The Postage

— Emily Cisek of The Postage. "I think advocating for myself and my business as a younger female founder has been a challenge mostly because as a person you want to please the people around you, investors, whoever, and sometimes no matter what you do, they aren't going to be on the same page and that's OK," she says. "But not carrying that forward is what's important. There's been times I've been told no, when I was trying to be exactly what I thought an investor or business partner wanted to hear."

"Typically, companies that have been around and have older leadership can have an advantage."

Photo via TMC.edu

— Emma Fauss of Medical Informatics Corp. She says she's experienced age discrimination early on within the health care industry.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”